Biohaven’s Life Without CGRP Inhibitors Gets Off To A Rocky Start

Data Mixed In Spinocerebellar Ataxia Study, But Zavegepant PDUFA Date Set

 
• By Mandy Jackson

With the sale of its migraine portfolio to Pfizer pending, Biohaven said troriluzole – a lead asset in the pipeline soon to be spun out in a new company – failed in a Phase III trial. 

Exotic rocky road to the crater of the volcano in the famous Caldera of Santorini island
The road to clinical success outside of its CGRP pipeline always has been rocky for Biohaven • Source: Shutterstock

More from Clinical Trials

More from R&D